

Ira Pastan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6808644/ira-pastan-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

400
papers

24,578
citations

82
h-index

142
g-index

406
ext. papers

26,456
ext. citations

8.5
avg, IF

6.79
L-index

#	Paper	IF	Citations
400	Biochemical, cellular, and pharmacological aspects of the multidrug transporter. <i>Annual Review of Pharmacology and Toxicology</i> , 1999 , 39, 361-98	17.9	1787
399	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 3360-5	11.5	637
398	Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. <i>New England Journal of Medicine</i> , 2001 , 345, 241-7	59.2	460
397	Immunotoxin therapy of cancer. <i>Nature Reviews Cancer</i> , 2006 , 6, 559-65	31.3	415
396	Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. <i>Somatic Cell and Molecular Genetics</i> , 1985 , 11, 117-26		413
395	Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. <i>Cell</i> , 1987 , 48, 129-36	56.2	400
394	A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. <i>Nature</i> , 1989 , 339, 394-7	50.4	397
393	Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1622-36	2.2	379
392	Mesothelin: a new target for immunotherapy. <i>Clinical Cancer Research</i> , 2004 , 10, 3937-42	12.9	352
391	Immunotoxin treatment of cancer. <i>Annual Review of Medicine</i> , 2007 , 58, 221-37	17.4	314
390	Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. <i>Clinical Cancer Research</i> , 2007 , 13, 5144-9	12.9	310
389	Recombinant toxins as novel therapeutic agents. <i>Annual Review of Biochemistry</i> , 1992 , 61, 331-54	29.1	294
388	Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. <i>Nature</i> , 1984 , 309, 806-10	50.4	273
387	Recombinant toxins for cancer treatment. <i>Science</i> , 1991 , 254, 1173-7	33.3	266
386	Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1822-8	2.2	261
385	Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. <i>Molecular Cancer</i> , 2006 , 5, 50	42.1	259
384	Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. <i>Nature</i> , 1988 , 335, 369-72	50.4	251

383	Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6719-29	2.2	242
382	Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. <i>Biochemistry</i> , 1998 , 37, 5010-9	3.2	229
381	Amines inhibit the clustering of alpha2-macroglobulin and EGF on the fibroblast cell surface. <i>Nature</i> , 1979 , 277, 661-3	50.4	229
380	Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 447-53	12.9	219
379	Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 1013-23	12.7	202
378	Improving antibody affinity by mimicking somatic hypermutation in vitro. <i>Nature Biotechnology</i> , 1999 , 17, 568-72	44.5	202
377	Lac DNA, RNA polymerase and cyclic AMP receptor protein, cyclic AMP, lac repressor and inducer are the essential elements for controlled lac transcription. <i>Nature: New Biology</i> , 1971 , 231, 139-42		199
376	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2003 , 65, 27-35	4.8	198
375	ATP-binding properties of P glycoprotein from multidrug-resistant KB cells. <i>FASEB Journal</i> , 1987 , 1, 51-40.9		194
374	Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. <i>Nature Medicine</i> , 1996 , 2, 350-3	50.5	191
373	Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. <i>International Journal of Cancer</i> , 1992 , 50, 373-81	7.5	191
372	Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2983-90	2.2	190
371	Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. <i>Clinical Cancer Research</i> , 2009 , 15, 5274-9	12.9	182
370	A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. <i>FEBS Journal</i> , 2011 , 278, 4683-700	5.7	180
369	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4171-4179	2.2	173
368	Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. <i>Science Translational Medicine</i> , 2013 , 5, 208ra147	17.5	169
367	Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. <i>Clinical Cancer Research</i> , 2011 , 17, 6398-405	12.9	168
366	Mesothelin is not required for normal mouse development or reproduction. <i>Molecular and Cellular Biology</i> , 2000 , 20, 2902-6	4.8	168

365	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. <i>Neuro-Oncology</i> , 2008 , 10, 320-9	1	160
364	The visualization of fluorescent proteins in living cells by video intensification microscopy (VIM). <i>Cell</i> , 1978 , 13, 501-7	56.2	158
363	Regulation of cell motility by cyclic AMP. <i>Nature</i> , 1972 , 235, 54-6	50.4	156
362	Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. <i>Clinical Cancer Research</i> , 2010 , 16, 6132-8	12.9	153
361	Discovery of mesothelin and exploiting it as a target for immunotherapy. <i>Cancer Research</i> , 2014 , 74, 2907-12	12	149
360	Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. <i>Journal of Immunology</i> , 2007 , 179, 4919-28	5.3	148
359	An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 11311-6	11.5	146
358	Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin. <i>Blood</i> , 1999 , 94, 3340-3348	2	145
357	Effects of calcium on ACTH stimulation of the adrenal: separation of hormone binding from adenyl cyclase activation. <i>Nature</i> , 1970 , 228, 864-6	50.4	145
356	A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. <i>Blood</i> , 2009 , 113, 3792-800	2.2	140
355	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. <i>Leukemia</i> , 2018 , 32, 1768-1777	10.7	136
354	Advances in anticancer immunotoxin therapy. <i>Oncologist</i> , 2015 , 20, 176-85	5.7	132
353	Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. <i>Clinical Cancer Research</i> , 2010 , 16, 1894-903	12.9	131
352	Localization of mesothelin in epithelial ovarian cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005 , 13, 243-7	1.9	130
351	Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 1992 , 16, 259-68	6.7	130
350	Both ATP sites of human P-glycoprotein are essential but not symmetric. <i>Biochemistry</i> , 1999 , 38, 13887-92	3.2	129
349	Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. <i>Nature Biotechnology</i> , 1996 , 14, 1239-45	44.5	127
348	Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. <i>Clinical Cancer Research</i> , 2005 , 11, 3814-20	12.9	126

347	Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. <i>Clinical Cancer Research</i> , 2014 , 20, 5927-36	12.9	125
346	Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 11782-7	11.5	125
345	Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. <i>Clinical Cancer Research</i> , 2002 , 8, 995-1002	12.9	125
344	Genetic basis of multidrug resistance of tumor cells. <i>Journal of Bioenergetics and Biomembranes</i> , 1990 , 22, 593-618	3.7	124
343	Effect of Rho on transcription of bacterial operons. <i>Nature: New Biology</i> , 1973 , 241, 260-4		121
342	Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. <i>Journal of Clinical Oncology</i> , 1991 , 9, 2095-103	2.2	119
341	3D Culture Supports Long-Term Expansion of Mouse and Human Nephrogenic Progenitors. <i>Cell Stem Cell</i> , 2016 , 19, 516-529	18	116
340	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. <i>Cancer</i> , 2014 , 120, 3311-9	6.4	115
339	Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. <i>Cancer Research</i> , 2011 , 71, 6300-9	10.1	108
338	Designed heterodimerizing leucine zippers with a ranger of pls and stabilities up to 10(-15) M. <i>Protein Science</i> , 2001 , 10, 649-55	6.3	107
337	Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors. <i>Blood</i> , 1997 , 90, 2020-2026	2.2	105
336	Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. <i>Neuro-Oncology</i> , 2007 , 9, 343-53	1	101
335	N 6 ,O 2 Qdibutyryl adenosine 3Qmonophosphate induces pigment production in melanoma cells. <i>Nature: New Biology</i> , 1972 , 237, 267-8		100
334	Mesothelin expression in human lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 1571-5	12.9	99
333	Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. <i>International Journal of Cancer</i> , 1994 , 58, 574-81	7.5	98
332	Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. <i>Cancer Research</i> , 2008 , 68, 6300-5	10.1	97
331	Characterization of CD22 expression in acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 964-9	3	96
330	CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. <i>Clinical Cancer Research</i> , 2009 , 15, 832-9	12.9	94

329	Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 8571-6	11.5	93
328	Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. <i>Clinical Cancer Research</i> , 2006 , 12, 4225-31	12.9	93
327	Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. <i>Biochemistry</i> , 1998 , 37, 13660-73	3.2	93
326	Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. <i>Journal of Immunology</i> , 2006 , 177, 8822-34	5.3	91
325	Immunotoxins for leukemia. <i>Blood</i> , 2014 , 123, 2470-7	2.2	89
324	Podocyte injury damages other podocytes. <i>Journal of the American Society of Nephrology: JASN</i> , 2011 , 22, 1275-85	12.7	88
323	New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. <i>Journal of Immunotherapy</i> , 2007 , 30, 607-13	5	88
322	Removing T-cell epitopes with computational protein design. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 8577-82	11.5	85
321	Targeted cytotoxic therapy kills persisting HIV infected cells during ART. <i>PLoS Pathogens</i> , 2014 , 10, e1003872	11.7	85
320	Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. <i>Operative Neurosurgery</i> , 2007 , 60, ONS89-98; discussion ONS98-9	1.6	85
319	Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 5742-7	11.5	84
318	Mesothelin-targeted agents in clinical trials and in preclinical development. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 517-25	6.1	82
317	Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. <i>Protein Engineering, Design and Selection</i> , 1994 , 7, 697-704	1.9	81
316	Immunotoxins containing Pseudomonas exotoxin A: a short history. <i>Cancer Immunology, Immunotherapy</i> , 2003 , 52, 338-41	7.4	80
315	Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. <i>Journal of Cellular Physiology</i> , 2000 , 183, 108-16	7	80
314	In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. <i>Journal of Biological Chemistry</i> , 2005 , 280, 607-17	5.4	79
313	Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. <i>Biochemistry</i> , 1998 , 37, 16400-9	3.2	79
312	Role of CAS, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and tumor necrosis factor mediated apoptosis. <i>Biochemistry</i> , 1996 , 35, 6891-9	3.2	78

311	Recombinant immunotoxins for treating cancer. <i>International Journal of Medical Microbiology</i> , 2004 , 293, 577-82	3.7	76
310	In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2040-9	6.1	75
309	Immunogenicity of therapeutic recombinant immunotoxins. <i>Immunological Reviews</i> , 2016 , 270, 152-64	11.3	75
308	A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 48-57	6.1	74
307	Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E3597-603	11.5	74
306	Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. <i>International Journal of Cancer</i> , 1999 , 81, 148-55	7.5	74
305	Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. <i>Journal of Urology</i> , 1994 , 151, 1396-9	2.5	74
304	HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. <i>Clinical Cancer Research</i> , 2005 , 11, 1545-50	12.9	73
303	Cytotoxic activities of a fusion protein comprised of TGF alpha and Pseudomonas exotoxin. <i>FASEB Journal</i> , 1989 , 3, 2647-52	0.9	73
302	Immunotoxins in the treatment of hematologic malignancies. <i>Current Drug Targets</i> , 2006 , 7, 1301-11	3	71
301	Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. <i>Journal of the National Cancer Institute</i> , 1991 , 83, 1386-91	9.7	70
300	Decreased binding of epidermal growth factor to BALB/c 3T3 mutant cells defective in glycoprotein synthesis. <i>Nature</i> , 1978 , 272, 68-70	50.4	69
299	Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. <i>Clinical Cancer Research</i> , 2006 , 12, 4695-701	12.9	67
298	Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 17099-104	11.5	67
297	POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta, and prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 16975-80	11.5	67
296	Recombinant immunotoxins in the treatment of cancer. <i>Methods in Molecular Biology</i> , 2004 , 248, 503-18	1.4	66
295	Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2010 , 150, 352-8	4.5	64
294	Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2009 , 61, 977-85	18.5	64

293	Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. <i>International Journal of Cancer</i> , 2000 , 87, 86-94	7.5	64
292	Cyclic AMP increases the Adhesion of Fibroblasts to Substratum. <i>Nature: New Biology</i> , 1972 , 236, 247-249		63
291	Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. <i>Bioconjugate Chemistry</i> , 1993 , 4, 112-20	6.3	62
290	Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. <i>American Journal of Roentgenology</i> , 2007 , 188, 703-9	5.4	61
289	Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. <i>Journal of Immunotherapy</i> , 2006 , 29, 208-14	5	61
288	Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. <i>International Journal of Cancer</i> , 2000 , 88, 962-9	7.5	61
287	Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2653-61	6.1	59
286	Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. <i>Journal of Controlled Release</i> , 2012 , 162, 218-24	11.7	58
285	Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. <i>Cancer Research</i> , 2008 , 68, 6306-12	10.1	58
284	Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. <i>Journal of Immunotherapy</i> , 2000 , 23, 473-9	5	58
283	Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. <i>Blood</i> , 2004 , 103, 2718-26	2.2	57
282	New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. <i>Clinical Cancer Research</i> , 2005 , 11, 5840-6 ¹²⁻⁹		57
281	Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. <i>Molecular and Cellular Biology</i> , 2010 , 30, 3444-52	4.8	56
280	Retroviruses expressing different levels of the normal epidermal growth factor receptor: biological properties and new bioassay. <i>Journal of Cellular Biochemistry</i> , 1989 , 39, 153-66	4.7	56
279	A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. <i>Biochemistry</i> , 1999 , 38, 6630-9	3.2	54
278	Interleukin-13 Receptors on Human Prostate Carcinoma Cell Lines Represent a Novel Target for a Chimeric Protein Composed of IL-13 and a Mutated Form of Pseudomonas Exotoxin. <i>Journal of Urology</i> , 1997 , 158, 948-953	2.5	53
277	High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. <i>Clinical Cancer Research</i> , 2008 , 14, 7981-6	12.9	53
276	Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2. <i>Journal of Immunology</i> , 2000 , 165, 7150-6	5.3	53

275	Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. <i>International Journal of Cancer</i> , 1992 , 51, 548-54	7.5	53
274	Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. <i>Kidney International</i> , 2013 , 83, 1065-73	9.9	52
273	Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. <i>Blood</i> , 2017 , 130, 1620-1627	2.2	51
272	Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation. <i>Kidney International</i> , 2014 , 85, 1068-77	9.9	51
271	Renaturation of a single-chain immunotoxin facilitated by chaperones and protein disulfide isomerase. <i>Nature Biotechnology</i> , 1992 , 10, 682-5	44.5	51
270	Targeting malignant B cells with an immunotoxin against ROR1. <i>MAbs</i> , 2012 , 4, 349-61	6.6	50
269	Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. <i>Proteins: Structure, Function and Bioinformatics</i> , 1994 , 19, 35-47	4.2	50
268	Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. <i>Nature Biotechnology</i> , 1994 , 12, 694-8	44.5	50
267	Molecular manipulations of the multidrug transporter: a new role for transgenic mice. <i>FASEB Journal</i> , 1991 , 5, 2523-8	0.9	50
266	Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin. <i>Journal of Cellular Physiology</i> , 1984 , 120, 271-9	7	49
265	Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. <i>Clinical Cancer Research</i> , 2002 , 8, 3520-6	12.9	49
264	A model for obesity and gigantism due to disruption of the Ankrd26 gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 270-5	11.5	48
263	POTE paralogs are induced and differentially expressed in many cancers. <i>Cancer Research</i> , 2006 , 66, 52-61	10.1	47
262	Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. <i>Clinical Cancer Research</i> , 2004 , 10, 16-8	12.9	47
261	High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. <i>Oncotarget</i> , 2015 , 6, 11694-703	3.3	47
260	Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. <i>International Journal of Cancer</i> , 1997 , 72, 512-7	7.5	45
259	Targeting Pseudomonas exotoxin to hematologic malignancies. <i>Seminars in Cancer Biology</i> , 1995 , 6, 297-306	3.6	45
258	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. <i>Blood</i> , 2018 , 131, 2331-2334	2.2	44

257	Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. <i>Journal of Neuro-Oncology</i> , 2010 , 98, 1-7	4.8	44
256	A novel high-affinity human monoclonal antibody to mesothelin. <i>International Journal of Cancer</i> , 2011 , 128, 2020-30	7.5	43
255	Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. <i>Neuro-Oncology</i> , 2005 , 7, 90-6	1	43
254	Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. <i>International Journal of Cancer</i> , 1994 , 57, 90-7	7.5	43
253	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. <i>Clinical Cancer Research</i> , 2016 , 22, 310-8	12.9	42
252	Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 6898-903	11.5	42
251	Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. <i>International Journal of Cancer</i> , 1994 , 58, 142-9	7.5	42
250	Sequence rearrangement and duplication of double stranded fibronectin cDNA probably occurring during cDNA synthesis by AMV reverse transcriptase and Escherichia coli DNA polymerase I. <i>Nucleic Acids Research</i> , 1980 , 8, 3055-64	20.1	41
249	Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. <i>PLoS Pathogens</i> , 2010 , 6, e1000803	7.6	40
248	Expression Cloning of cDNAs That Render Cancer Cells Resistant to Pseudomonas and Diphtheria Toxin and Immunotoxins. <i>Molecular Medicine</i> , 1995 , 1, 206-216	6.2	40
247	New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene. <i>Journal of Urology</i> , 1991 , 146, 447-53	2.5	40
246	DNA immunization followed by a single boost with cells: a protein-free immunization protocol for production of monoclonal antibodies against the native form of membrane proteins. <i>Journal of Immunological Methods</i> , 2003 , 280, 59-72	2.5	39
245	Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. <i>Nature Medicine</i> , 1999 , 5, 817-22	50.5	39
244	Cyclic AMP and growth of fibroblasts: effect of environmental pH. <i>Nature: New Biology</i> , 1973 , 242, 78-80		39
243	Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. <i>Clinical Cancer Research</i> , 2011 , 17, 3697-705	12.9	38
242	FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. <i>Blood</i> , 2008 , 111, 338-43	2.2	38
241	Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths. <i>Gene</i> , 2004 , 337, 45-53	3.8	38
240	Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 4575-4582	11.5	38

239	Ankrd26 gene disruption enhances adipogenesis of mouse embryonic fibroblasts. <i>Journal of Biological Chemistry</i> , 2011 , 286, 27761-8	5.4	37
238	Retroviral transfer of a chimeric multidrug resistance-adenosine deaminase gene. <i>FASEB Journal</i> , 1990 , 4, 1501-7	0.9	36
237	Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins. <i>American Journal of Pathology</i> , 2018 , 188, 1736-1743	5.8	35
236	A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. <i>Cancer Research</i> , 2010 , 70, 1082-9	10.1	35
235	Evolution and expression of chimeric POTE-actin genes in the human genome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 17885-90	11.5	35
234	PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 3058-63	11.5	35
233	Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1994 , 21, 640-6		35
232	Role of Cyclic Adenosine 3',5'-Monophosphate and the Cyclic Adenosine 3',5'-Monophosphate Receptor Protein in the Initiation of lac Transcription. <i>Journal of Biological Chemistry</i> , 1971 , 246, 7343-7348	5.4	35
231	Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy. <i>Molecular Oncology</i> , 2016 , 10, 1317-29	7.9	34
230	Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. <i>Cancer Research</i> , 2012 , 72, 3143-52	10.1	34
229	A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. <i>Journal of Immunotherapy</i> , 2010 , 33, 297-304	5	34
228	Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. <i>Biochemistry</i> , 1994 , 33, 5894-900	3.2	34
227	Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 10666-71	11.5	34
226	Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated α -integrin endocytosis. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 308, F614-26	4.3	33
225	A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2. <i>Journal of Molecular Biology</i> , 1998 , 281, 475-83	6.5	33
224	On the mechanism of action of lac repressor. <i>Nature: New Biology</i> , 1971 , 233, 67-70		33
223	Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. <i>Oncotarget</i> , 2016 , 7, 29916-26	3.3	33
222	Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E3501-E3508	11.5	32

221	Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice. <i>Journal of Urology</i> , 1993 , 149, 174-8	2.5	32
220	Regulation of intracellular calcium in chick embryo fibroblast: calcium uptake by the microsomal fraction. <i>Journal of Cellular Physiology</i> , 1977 , 91, 289-96	7	32
219	Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E733-E742	11.5	31
218	A primate-specific POTE-actin fusion protein plays a role in apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009 , 14, 1237-44	5.4	31
217	ATP and GTP as alternative energy sources for vinblastine transport by P-170 in KB-V1 plasma membrane vesicles. <i>FEBS Letters</i> , 1992 , 304, 256-60	3.8	31
216	Safety and biodistribution of ¹¹¹ In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. <i>Oncotarget</i> , 2015 , 6, 4496-504	3.3	31
215	Podocyte injury-driven lipid peroxidation accelerates the infiltration of glomerular foam cells in focal segmental glomerulosclerosis. <i>American Journal of Pathology</i> , 2015 , 185, 2118-31	5.8	30
214	Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2789-96	6.1	30
213	Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. <i>International Journal of Cancer</i> , 1995 , 62, 351-5	7.5	30
212	Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines. <i>Journal of Cellular Physiology</i> , 1992 , 152, 87-94	7	30
211	Cancer vaccine strategies: translation from mice to human clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1863-1869	7.4	30
210	New Life for Immunotoxin Cancer Therapy. <i>Clinical Cancer Research</i> , 2016 , 22, 1055-8	12.9	29
209	Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 1039-46	6.1	29
208	PRAC: A novel small nuclear protein that is specifically expressed in human prostate and colon. <i>Prostate</i> , 2001 , 47, 125-31	4.2	29
207	Cytotoxic activity of chimeric proteins composed of acidic fibroblast growth factor and Pseudomonas exotoxin on a variety of cell types. <i>FASEB Journal</i> , 1991 , 5, 2843-9	0.9	29
206	A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2011 , 118, 248-248	2.2	29
205	GDEP, a new gene differentially expressed in normal prostate and prostate cancer. <i>Prostate</i> , 2001 , 48, 231-41	4.2	28
204	Cse1l is essential for early embryonic growth and development. <i>Molecular and Cellular Biology</i> , 2001 , 21, 7020-4	4.8	28

203	111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. <i>International Journal of Cancer</i> , 1999 , 80, 559-63	7.5	28
202	Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. <i>Clinical Cancer Research</i> , 2002 , 8, 2345-55	12.9	28
201	Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo. <i>Cellular and Molecular Immunology</i> , 2017 , 14, 432-442	15.4	27
200	Loss of diphthamide pre-activates NF- κ B and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 10732-7	11.5	27
199	Immunogenicity of Immunotoxins Containing Exotoxin A: Causes, Consequences, and Mitigation. <i>Frontiers in Immunology</i> , 2020 , 11, 1261	8.4	27
198	An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. <i>Leukemia Research</i> , 2014 , 38, 1224-9	2.7	27
197	Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. <i>Biomaterials</i> , 2013 , 34, 8718-8725	15.6	27
196	A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. <i>Protein Engineering, Design and Selection</i> , 2012 , 25, 1-6	1.9	27
195	Antisense inhibition of CAS, the human homologue of the yeast chromosome segregation gene CSE1, interferes with mitosis in HeLa cells. <i>Biochemistry</i> , 1997 , 36, 9493-500	3.2	27
194	Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3. <i>Journal of Biological Chemistry</i> , 1995 , 270, 23373-80	5.4	27
193	Multidrug resistant transgenic mice as a novel pharmacologic tool. <i>BioEssays</i> , 1991 , 13, 381-7	4.1	27
192	Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. <i>Oncotarget</i> , 2017 , 8, 32450-32460	3.3	26
191	Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins. <i>European Journal of Immunology</i> , 1997 , 27, 1459-68	6.1	26
190	Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. <i>Journal of Leukocyte Biology</i> , 2006 , 80, 1175-82	6.5	26
189	Detection of multidrug resistance (MDR1) gene RNA expression in human tumors by a sensitive ribonuclease protection assay. <i>Japanese Journal of Cancer Research</i> , 1989 , 80, 1127-32		26
188	Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. <i>Oncotarget</i> , 2017 , 8, 26744-26754	3.3	26
187	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. <i>Clinical Cancer Research</i> , 2017 , 23, 1564-1574	12.9	25
186	A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene. <i>Journal of Biological Chemistry</i> , 2013 , 288, 12305-12	5.4	25

185	Characterization of the 3,3',5-triiodo-L-thyronine-binding site on plasma membranes from human placenta. <i>Endocrinology</i> , 1985 , 116, 2621-30	4.8	25
184	Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury. <i>Kidney International</i> , 2017 , 92, 1395-1403	9.9	24
183	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. <i>Cancer Immunology Research</i> , 2017 , 5, 685-694	12.5	24
182	Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model. <i>International Journal of Cancer</i> , 1994 , 57, 856-64	7.5	24
181	A calcium requirement for movement of cultured cells. <i>Journal of Cellular Physiology</i> , 1979 , 101, 101-8	7	24
180	New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma. <i>Scientific Reports</i> , 2015 , 5, 9928	4.9	23
179	5QTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 18	22.4	23
178	Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights. <i>Journal of Biological Chemistry</i> , 2012 , 287, 33123-31	5.4	23
177	Isolation of anti-mesothelin antibodies from a phage display library. <i>Molecular Immunology</i> , 1997 , 34, 9-20	4.3	23
176	Translocation chromosome 7 of A431 cells contains amplification and rearrangement of EGF receptor gene responsible for production of variant mRNA. <i>Somatic Cell and Molecular Genetics</i> , 1985 , 11, 477-84		23
175	Diminished content of plasma membrane-associated myosin in transformed fibroblasts. <i>Nature</i> , 1976 , 261, 414-5	50.4	23
174	Convection enhanced delivery of macromolecules for brain tumors. <i>Current Drug Discovery Technologies</i> , 2012 , 9, 305-10	1.5	23
173	Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. <i>Hepatology</i> , 2020 , 71, 1696-1711	11.2	23
172	Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A. <i>Bioconjugate Chemistry</i> , 2015 , 26, 1120-8	6.3	22
171	Immunoconjugates in the management of hairy cell leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2015 , 28, 236-45	4.2	22
170	Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. <i>British Journal of Haematology</i> , 2010 , 148, 99-109	4.5	22
169	Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. <i>Cancer Research</i> , 2011 , 71, 5915-22	10.1	22
168	Studies on the activity of barnase toxins in vitro and in vivo. <i>Bioconjugate Chemistry</i> , 1996 , 7, 23-9	6.3	22

167	Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8. <i>Leukemia Research</i> , 2013 , 37, 1551-6	2.7	21
166	ANKRD26 and its interacting partners TRIO, GPS2, HMMR and DIPA regulate adipogenesis in 3T3-L1 cells. <i>PLoS ONE</i> , 2012 , 7, e38130	3.7	21
165	Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody. <i>Clinical Cancer Research</i> , 2011 , 17, 5926-34	12.9	21
164	Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A. <i>Journal of Immunological Methods</i> , 2015 , 425, 10-20	2.5	20
163	Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. <i>International Journal of Cancer</i> , 2011 , 129, 111-21	7.5	20
162	Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52 Suppl 2, 82-6	1.9	20
161	Toxin-based targeted therapy for malignant brain tumors. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 480429		20
160	Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. <i>Journal of Immunological Methods</i> , 2004 , 292, 141-55	2.5	20
159	Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin. <i>International Journal of Cancer</i> , 2001 , 92, 861-70	7.5	20
158	Attenuating the growth of tumors by intratumoral administration of DNA encoding Pseudomonas exotoxin via cationic liposomes. <i>Cancer Gene Therapy</i> , 2000 , 7, 91-6	5.4	20
157	Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient@ Bedside to Evaluation in Preclinical Models. <i>Toxins</i> , 2019 , 11,	4.9	19
156	Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E1135-42	11.5	19
155	Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. <i>Clinical Cancer Research</i> , 2012 , 18, 152-60	12.9	19
154	Immunotoxins in the treatment of refractory hairy cell leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2006 , 20, 1137-51, viii	3.1	19
153	The T cell receptor gamma chain alternate reading frame protein (TARP), a prostate-specific protein localized in mitochondria. <i>Journal of Biological Chemistry</i> , 2004 , 279, 24561-8	5.4	19
152	Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc. <i>Bioconjugate Chemistry</i> , 1999 , 10, 447-53	6.3	19
151	Cyclic AMP-treated sarcoma cells acquire several morphological characteristics of normal fibroblasts. <i>Annals of the New York Academy of Sciences</i> , 1971 , 185, 413-6	6.5	19
150	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Oncolimmunology</i> , 2016 , 5, e1197459	7.2	19

149	Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38. <i>Cellular Immunology</i> , 2017 , 313, 59-66	4.4	18
148	Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells. <i>Journal of Immunotherapy</i> , 2014 , 37, 8-15	5	18
147	Imaging of convection enhanced delivery of toxins in humans. <i>Toxins</i> , 2011 , 3, 201-6	4.9	18
146	Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: Conformational influence of an engineered disulfide bond. <i>Proteins: Structure, Function and Bioinformatics</i> , 1998 , 31, 1284-138	4.2	18
145	Recombinant immunotoxins. <i>Breast Cancer Research and Treatment</i> , 1996 , 38, 3-9	4.4	18
144	Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin. <i>International Journal of Cancer</i> , 1994 , 58, 744-8	7.5	18
143	Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. <i>Journal of Cellular Physiology</i> , 1993 , 155, 414-25	7	18
142	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 828-836	12.9	18
141	Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results. <i>Scientific Reports</i> , 2015 , 5, 10832	4.9	17
140	Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury. <i>PLoS ONE</i> , 2014 , 9, e89135	3.7	17
139	The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin. <i>Cancer Research</i> , 2013 , 73, 2281-8	10.1	17
138	Immunotoxins with decreased immunogenicity and improved activity. <i>Leukemia and Lymphoma</i> , 2011 , 52 Suppl 2, 87-90	1.9	17
137	Selective POTE paralogs on chromosome 2 are expressed in human embryonic stem cells. <i>Stem Cells and Development</i> , 2008 , 17, 325-32	4.4	17
136	EGF induces receptor down-regulation with no receptor recycling in KB cells. <i>Journal of Cellular Physiology</i> , 1985 , 122, 166-70	7	17
135	Regulation of Lac Transcription in Escherichia coli by Cyclic Adenosine 3',5'-Cyclic Monophosphate. <i>Journal of Biological Chemistry</i> , 1970 , 245, 6366-6372	5.4	17
134	Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A. <i>Toxins</i> , 2016 , 8,	4.9	17
133	Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. <i>BMC Cancer</i> , 2015 , 15, 376	4.8	16
132	Effect of epidermal growth factor on prostaglandin E1-stimulated accumulation of cyclic AMP in fibroblastic cells. <i>FEBS Letters</i> , 1979 , 102, 329-32	3.8	16

131	Inhibition by bacitracin of high affinity binding of 125I-alpha 2M to plasma membranes. <i>FEBS Letters</i> , 1981 , 126, 265-8	3.8	16
130	Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. <i>Anticancer Research</i> , 2012 , 32, 5151-8	2.3	16
129	Anti-TGF- β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria. <i>PLoS ONE</i> , 2016 , 11, e0155534	3.7	16
128	Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1648-55	6.1	15
127	Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 82-9	6.1	15
126	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 35	22.4	15
125	Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. <i>Cancer Research</i> , 2016 , 76, 1560-8	10.1	14
124	CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 433-43	9.5	14
123	Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. <i>International Journal of Cancer</i> , 1997 , 71, 638-44	7.5	14
122	Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability. <i>Bioconjugate Chemistry</i> , 1998 , 9, 736-43	6.3	14
121	Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. <i>International Journal of Cancer</i> , 1996 , 67, 113-23	7.5	14
120	Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway. <i>Oncotarget</i> , 2017 , 8, 87307-87316	3.3	14
119	Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia. <i>Oncologist</i> , 2020 , 25, e170-e177	5.7	14
118	Approach to the patient after relapse of hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50 Suppl 1, 32-7	1.9	13
117	The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan. <i>MAbs</i> , 2011 , 3, 479-86	6.6	13
116	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. <i>Lung Cancer</i> , 2016 , 101, 104-110	5.9	13
115	SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors. <i>Toxins</i> , 2018 , 10,	4.9	13
114	Podocyte Injury Augments Intrarenal Angiotensin II Generation and Sodium Retention in a Megalin-Dependent Manner. <i>Hypertension</i> , 2019 , 74, 509-517	8.5	12

113	Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. <i>British Journal of Haematology</i> , 2014 , 166, 729-38	4.5	12
112	Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE. <i>PLoS ONE</i> , 2013 , 8, e64365	3.7	12
111	Autonomic neuropathy in transgenic mice caused by immunotoxin targeting of the peripheral nervous system. <i>Journal of Neuroscience Research</i> , 1998 , 51, 162-73	4.4	12
110	Expression of POTE protein in human testis detected by novel monoclonal antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 365, 603-8	3.4	12
109	Fluorescent rhodamine-labeled thyroid hormone derivatives: synthesis and binding to the thyroid hormone nuclear receptor. <i>FEBS Letters</i> , 1979 , 100, 113-6	3.8	12
108	Immunotoxins in cancer therapy. <i>Current Opinion in Investigational Drugs</i> , 2002 , 3, 1089-91		12
107	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	11
106	Improving the Efficacy of an Anti-Tac (CD25) Immunotoxin by Exotoxin A Domain II Engineering. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1486-1493	6.1	11
105	Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. <i>Leukemia and Lymphoma</i> , 2011 , 52 Suppl 2, 79-81	1.9	11
104	An epidermal growth factor-ricin A chain (EGF-RTA)-resistant mutant and an epidermal growth factor-Pseudomonas endotoxin (EGF-PE)-resistant mutant have distinct phenotypes. <i>Journal of Cellular Physiology</i> , 1989 , 139, 51-7	7	11
103	In situ localization of the human multidrug-resistance gene mRNA using thymine-thymine dimerized single-stranded cDNA. <i>Japanese Journal of Cancer Research</i> , 1990 , 81, 949-55		11
102	Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary. <i>PLoS ONE</i> , 2012 , 7, e47320	3.7	11
101	Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P. <i>PLoS ONE</i> , 2013 , 8, e75576	3.7	11
100	Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line. <i>PLoS ONE</i> , 2015 , 10, e0122462	3.7	11
99	EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery. <i>Receptors & Clinical Investigation</i> , 2016 , 3,		11
98	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020 , 126, 4936-4947	6.4	11
97	Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 4592-4598	11.5	11
96	Diphthamide affects selenoprotein expression: Diphthamide deficiency reduces selenocysteine incorporation, decreases selenite sensitivity and pre-disposes to oxidative stress. <i>Redox Biology</i> , 2019 , 20, 146-156	11.3	11

95	Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model. <i>PLoS ONE</i> , 2014 , 9, e110716	3.7	10
94	POTE protein, a cancer-testis antigen, is highly expressed in spermatids in human testis and is associated with apoptotic cells. <i>Biochemical and Biophysical Research Communications</i> , 2012 , 417, 1271-4	3.4	10
93	Mutant KB cells with decreased EGF receptor expression: biochemical characterization. <i>Journal of Cellular Physiology</i> , 1987 , 133, 127-34	7	10
92	Genetic characterization of human KB cell lines resistant to epidermal growth factor: Pseudomonas exotoxin conjugates. <i>Journal of Cellular Physiology</i> , 1988 , 135, 527-32	7	10
91	Purification and Partial Characterization of an Interleukin 2-Pseudomonas Exotoxin Fusion Protein. <i>Nature Biotechnology</i> , 1988 , 6, 1326-1329	44.5	10
90	5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E1867-E1875	11.5	9
89	Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1053-62	6.1	9
88	Rous sarcoma virus transformed cells are resistant to cyclic AMP. <i>Journal of Cellular Physiology</i> , 1982 , 111, 42-8	7	9
87	Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 812-821	6.1	9
86	Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28112	3	8
85	Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies. <i>Nuclear Medicine and Biology</i> , 2015 , 42, 880-6	2.1	8
84	Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice. <i>Journal of Immunology</i> , 2015 , 194, 1695-701	5.3	8
83	Anti-prostate immunotoxins: cytotoxicity of E4 antibody-Pseudomonas exotoxin constructs. <i>International Journal of Cancer</i> , 1998 , 77, 123-7	7.5	8
82	Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma. <i>Prostate</i> , 1998 , 36, 162-7	4.2	8
81	Efficient ablation by immunotoxin-mediated cell targeting of the cell types that express human interleukin-2 receptor depending on the internal ribosome entry site. <i>Journal of Gene Medicine</i> , 2001 , 3, 505-10	3.5	8
80	Epidermal growth factor-dependent growth of human KB cells in a defined medium and altered growth factor requirements of KB mutants resistant to EGF-Pseudomonas exotoxin conjugates. <i>Journal of Cellular Physiology</i> , 1988 , 135, 502-8	7	8
79	Phosphorylation of the solubilized insulin receptor by the gene product of the Rous sarcoma virus, pp60src. <i>Journal of Cellular Biochemistry</i> , 1984 , 26, 169-79	4.7	8
78	Reduction of EGF receptor synthesis by antisense RNA vectors. <i>FEBS Letters</i> , 1986 , 206, 319-22	3.8	8

77	Development of Recombinant Immunotoxins for Hairy Cell Leukemia. <i>Biomolecules</i> , 2020 , 10,	5.9	8
76	Possible role of complement factor H in podocytes in clearing glomerular subendothelial immune complex deposits. <i>Scientific Reports</i> , 2019 , 9, 7857	4.9	7
75	Lipoprotein modulation of proteinuric renal injury. <i>Laboratory Investigation</i> , 2019 , 99, 1107-1116	5.9	7
74	Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2012 , 68, 950-3		7
73	Palmitoylation of POTE family proteins for plasma membrane targeting. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 363, 751-6	3.4	7
72	Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial. <i>Blood</i> , 2019 , 134, 2808-2808	2.2	7
71	Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.. <i>Blood</i> , 2009 , 114, 888-888	2.2	7
70	Recombinant Immunotoxins for Treating Cancer 2010 , 127-146		7
69	Mechanisms of Resistance to Immunotoxins Containing Exotoxin A in Cancer Therapy. <i>Biomolecules</i> , 2020 , 10,	5.9	7
68	Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1. <i>Cellular Immunology</i> , 2018 , 334, 38-41	4.4	7
67	Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma. <i>Antibody Therapeutics</i> , 2018 , 1, 19-25	5.8	7
66	Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1367-1376	3.8	6
65	Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin. <i>Journal of Immunology</i> , 2018 , 200, 2038-2045	5.3	6
64	Sensitivity of human acute myeloid leukaemia to diphtheria toxin-GM-CSF fusion protein. <i>British Journal of Haematology</i> , 1997 , 98, 952-9	4.5	6
63	Putative "MDR enhancer" is located on human chromosome 20 and not linked to the MDR1 gene on chromosome 7. <i>Genes Chromosomes and Cancer</i> , 1994 , 10, 267-74	5	6
62	Cytotoxic effect of a fusion protein from transforming growth factor alpha and Pseudomonas exotoxin on rat and human bladder carcinoma cells in vitro. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994 , 120, 507-12	4.9	6
61	Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2009 , 114, 839-839	2.2	6
60	Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins. <i>PLoS ONE</i> , 2016 , 11, e0161415	3.7	6

59	Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies. <i>Oncotarget</i> , 2017 , 8, 30644-30655	3.3	6
58	Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. <i>Oncology Letters</i> , 2020 , 19, 1741-1750	2.6	6
57	Advances in the Development of Anti-CD22 Immunotoxins Containing Pseudomonas Exotoxin for Treatment of Hematologic Malignancies. <i>Journal of Cancer Science & Therapy</i> , 2011 , 03,	5	6
56	Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 6086-6091	11.5	5
55	Domain II of Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia. <i>Toxins</i> , 2018 , 10,	4.9	5
54	Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 192-199.e1	3.8	5
53	TGF β PE38 enhances cytotoxic T-lymphocyte killing of breast cancer cells. <i>Oncology Letters</i> , 2014 , 7, 2113-2117	2.6	5
52	Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006 , 44, 594-602	5.9	5
51	Pseudomonas exotoxin: recombinant conjugates as therapeutic agents. <i>Biochemical Society Transactions</i> , 1992 , 20, 731-4	5.1	5
50	Global polysome analysis of normal and injured podocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 316, F241-F252	4.3	5
49	Immunotherapy-based targeting of MSLN activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	5
48	Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin. <i>AAPS Journal</i> , 2017 , 19, 117-129	3.7	4
47	Effect of cell density on energy-dependent calcium uptake by Balb/c 3T3 membranes is independent of protein synthesis and attachment to substratum. <i>Journal of Cellular Physiology</i> , 1979 , 101, 109-16	7	4
46	Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice. <i>PLoS ONE</i> , 2014 , 9, e104388	3.7	4
45	The cellular entry of EGF and transferrin: a problem in intracellular sorting. <i>Current Topics in Cellular Regulation</i> , 1985 , 26, 17-25		4
44	Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design. <i>Clinical Cancer Research</i> , 2016 , 22, 4913-4922	12.9	4
43	Stabilization of hypoxia-inducible factor ameliorates glomerular injury sensitization after tubulointerstitial injury. <i>Kidney International</i> , 2021 , 99, 620-631	9.9	4
42	Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. <i>journal of applied laboratory medicine, The</i> , 2018 , 3, 166-177	2	4

41	Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccines. <i>The Histochemical Journal</i> , 1999 , 31, 729-37		3
40	Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy. <i>Blood</i> , 2011 , 118, 2575-2575	2.2	3
39	Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. <i>Blood</i> , 2013 , 122, 2871-2871	2.2	3
38	High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome. <i>Blood</i> , 2015 , 126, 4161-4161	2.2	3
37	A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 307-307	2.2	3
36	Multiple proteases are involved in mesothelin shedding by cancer cells. <i>Communications Biology</i> , 2020 , 3, 728	6.7	3
35	Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2812-2814	1.9	3
34	Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens. <i>Journal of Biomolecular Screening</i> , 2016 , 21, 942-55		3
33	Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy. <i>Journal of Immunotherapy</i> , 2019 , 42, 119-125	5	3
32	Interactions Between Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy. <i>Frontiers in Oncology</i> , 2018 , 8, 553	5.3	3
31	Adenylate cyclase in a fibroblast mutant defective in glycolipid and glycoprotein synthesis. <i>Nature</i> , 1978 , 275, 223-4	50.4	2
30	Abstract 4510: RG7787 - a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors 2014 ,		2
29	Pre-Clinical Evaluation of the Anti-CD22 Immunotoxin CAT-8015 in Combination with Chemotherapy Agents for Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL).. <i>Blood</i> , 2007 , 110, 865-865	2.2	2
28	Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox. <i>Blood</i> , 2010 , 116, 3246-3246	2.2	2
27	Mesothelin expression in patients as a novel target in gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 61-61	2.2	2
26	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3051-3051	2.2	2
25	Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake 2000 , 183, 108		2
24	Unilateral ureteral obstruction attenuates intrarenal angiotensin II generation induced by podocyte injury. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 308, F932-7	4.3	1

23	Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015 , 57-73	0.3	1
22	Exploiting bias in a non-immune human antibody library to predict antigenicity. <i>Protein Engineering, Design and Selection</i> , 2011 , 24, 845-53	1.9	1
21	Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen. <i>Japanese Journal of Cancer Research</i> , 1998 , 89, 436-44		1
20	An NIH career: from bedside to basic research and back. <i>Journal of Biological Chemistry</i> , 2005 , 280, 18553-7	3.7	1
19	BL22, a Recombinant Anti-CD22 Immunotoxin, Induces Cell Cycle Arrest and Apoptosis in B-Cell Lymphoma.. <i>Blood</i> , 2004 , 104, 4613-4613	2.2	1
18	Targeting CD22 in Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL): Pre-Clinical Studies and Phase I Trial of the Anti-CD22 Immunotoxin CAT-3888 (BL22).. <i>Blood</i> , 2007 , 110, 855-855	2.2	1
17	Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.. <i>Blood</i> , 2009 , 114, 3442-3442	2.2	1
16	Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7079-7079	2.2	1
15	A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 102-102	2.2	1
14	Interplay between reversible phosphorylation and irreversible ADP-ribosylation of eukaryotic translation elongation factor 2. <i>Biological Chemistry</i> , 2019 , 400, 501-512	4.5	1
13	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS452-TPS452	2.2	1
12	Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.. <i>Blood</i> , 2012 , 120, 2896-2896	2.2	0
11	Indirect podocyte injury manifested in a partial podocytectomy mouse model. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 320, F922-F933	4.3	0
10	Clinical Applications of Gene Therapy in Cancer: Modification of Sensitivity to Therapeutic Agents	429-453	
9	IL-2 non-responsive subset of human natural regulatory T cells expresses Fc receptor-like 3 protein. <i>FASEB Journal</i> , 2008 , 22, 381-381	0.9	
8	Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7014-7014	2.2	
7	Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 74-74	2.2	
6	Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2503-2503	2.2	

- 5 Decreased Expression of Diphthamide Genes Is Responsible for the Resistance to the Anti-CD22 Immunotoxin Moxetumomab Pasudotox (m. pasudotox) in Acute Lymphoblastic Leukemia (ALL)/Non-Hodgkin Lymphoma (NHL) Cell Lines.. *Blood*, **2012**, 120, 2443-2443 2.2
- 4 The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.. *Blood*, **2012**, 120, 2488-2488 2.2
- 3 A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.. *Blood*, **2012**, 120, 2611-2611 2.2
- 2 Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.. *Journal of Clinical Oncology*, **2021**, 39, 7036-7036 2.2
- 1 Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2202439119 11.5